{"name":"DermBiont, Inc.","slug":"dermbiont-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"SM-020","genericName":"SM-020","slug":"sm-020","indication":"Other","status":"phase_2"},{"name":"SM-020 gel 1.0%","genericName":"SM-020 gel 1.0%","slug":"sm-020-gel-1-0","indication":"Other","status":"phase_2"},{"name":"SM-030 gel 0.64%","genericName":"SM-030 gel 0.64%","slug":"sm-030-gel-0-64","indication":"Other","status":"phase_2"},{"name":"DBI-001 Gel","genericName":"DBI-001 Gel","slug":"dbi-001-gel","indication":"Other","status":"phase_2"},{"name":"DBI-102","genericName":"DBI-102","slug":"dbi-102","indication":"Other","status":"phase_2"},{"name":"SM-020 1% Gel","genericName":"SM-020 1% Gel","slug":"sm-020-1-gel","indication":"Other","status":"phase_2"},{"name":"SM-030 gel 0.08%","genericName":"SM-030 gel 0.08%","slug":"sm-030-gel-0-08","indication":"Other","status":"phase_2"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"DBI-002 Gel","genericName":"DBI-002 Gel","slug":"dbi-002-gel","indication":"Moderate to severe atopic dermatitis","status":"phase_2"}]}],"pipeline":[{"name":"SM-020","genericName":"SM-020","slug":"sm-020","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SM-020 gel 1.0%","genericName":"SM-020 gel 1.0%","slug":"sm-020-gel-1-0","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SM-030 gel 0.64%","genericName":"SM-030 gel 0.64%","slug":"sm-030-gel-0-64","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DBI-001 Gel","genericName":"DBI-001 Gel","slug":"dbi-001-gel","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"DBI-002 Gel","genericName":"DBI-002 Gel","slug":"dbi-002-gel","phase":"phase_2","mechanism":"DBI-002 Gel is a topical treatment that modulates the skin microbiome to improve symptoms of atopic dermatitis.","indications":["Moderate to severe atopic dermatitis"],"catalyst":""},{"name":"DBI-102","genericName":"DBI-102","slug":"dbi-102","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SM-020 1% Gel","genericName":"SM-020 1% Gel","slug":"sm-020-1-gel","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SM-030 gel 0.08%","genericName":"SM-030 gel 0.08%","slug":"sm-030-gel-0-08","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPWTRIa2VubVlCZ2VKVms4Ym1CR0JOQVFXMXNYZjVidnUxdjRETjd3a2hhMWY0bmRxUm9qbWpkNkdYZlotalJrWDFUY2F6LTE4anpTUUR0N0h1YlM1OWV0dWVvSjJFQ2JSTUFfT2E0dFFhdzFSQTAxR1hDMlRLbDczWF81TTFWcTBjWDNkQmlHNkNfY1FZd2c?oc=5","date":"2025-04-01","type":"pipeline","source":"citybiz","summary":"Phathom Pharmaceuticals Appoints Steven Basta as CEO - citybiz","headline":"Phathom Pharmaceuticals Appoints Steven Basta as CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQYkhBV2psN1dFYXM4TXh1LXlWRTBjTWVoWC0wS3h6UUVYVUhHVlF3R1hzS2oxZjVXZEloaGRXdFVYdWRDN3hrVFpEcVFOVi1vNHNMbWFpZjc2WXRLaXc2QTNUMnJjX1BybWpxdGlKTzdmOXRKUHhNZUc2RzR4YUNZOWRKMFk0YWRQdlpxRW9LRkNPMmJv?oc=5","date":"2024-06-18","type":"regulatory","source":"openPR.com","summary":"Tinea Pedis Market Outlook 2032: FDA Approvals, Clinical - openPR.com","headline":"Tinea Pedis Market Outlook 2032: FDA Approvals, Clinical","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxObjN6V2t5c2lVOEYxYU8xYmpudnJtRW9fTlBaOEhldlA0Y3R2UVFhQTdKUnVBVGpobTN2ODJWSXhRSUZPcHZvdHNBQ0NXRzNqTHB0cHREWThKSFhUdmdvTWdjRHdtOTlrclFPcWJ1bEM4b3JnbUU4dzA1YlpCNWxKaHVyLWxlNE5vOUU0S01EY1loUUZKZEZyUUVQUEFJelZ0Mkw3RzVpSzhtM0FuYW05bUJ2V01NVE5rNXo3QWREckNaeFpHLXhUOUpWVzRSeDJSd29nc29QUDRrSmx5NzlyeTZESWRKRkNXRVdMZGlkTU9tUGdIN0diUUd3?oc=5","date":"2021-12-21","type":"deal","source":"Business Wire","summary":"DermBiont Raises $28 Million and Acquires Chromaderm to Expand Targeted Topical Therapeutics in Development - Business Wire","headline":"DermBiont Raises $28 Million and Acquires Chromaderm to Expand Targeted Topical Therapeutics in Development","sentiment":"neutral"}],"patents":[],"drugCount":8,"phaseCounts":{"phase_2":8},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}